GenoType CM Direct® and VisionArray Myco® for the Rapid Identification of Mycobacteria from Clinical Specimens
- PMID: 35566531
- PMCID: PMC9103381
- DOI: 10.3390/jcm11092404
GenoType CM Direct® and VisionArray Myco® for the Rapid Identification of Mycobacteria from Clinical Specimens
Abstract
M. tuberculosis is the single infectious agent responsible for most deaths worldwide outside of pandemics. Diseases due to non-tuberculous mycobacteria (NTM) are increasing in many regions of the world. The two molecular assays GenoType CM direct® (GTCMd) (Bruker, Billerica, MA, USA) and VisionArray Myco® (VAM) (ZytoVision, Bremerhaven, Germany) are based on the DNA/DNA hybridization technique, and allow for the identification of tuberculous and the most clinically relevant non-tuberculous mycobacterial species from clinical specimens. We evaluated the performance of both assays for the identification of mycobacteria from 65 clinical specimens of 65 patients and compared it with the results of conventional culture. Based on conventional culture that recovered 37 mycobacterial isolates including 11 tuberculous and 26 NTM isolates, sensitivity, specificity, positive predictive value and negative predictive value were 89.2%, 81.5%, 86.8% and 84.6% for GTCMd and 73.0%, 96.3%, 96.4% and 72.2% for VAM. Additionally, GTCMd identified mycobacteria from five and VAM from one culture-negative sample. Both assays identified a mycobacterium in one sample overgrown by other microorganisms. Two M. abscessus subsp. abscessus isolates grown from culture were identified as M. chelonae by GTCMd assay. In conclusion, both assays improve the rapid identification of mycobacteria directly from clinical specimens.
Keywords: NTM; molecular identification; non-tuberculous mycobacteria; rapid diagnostic test.
Conflict of interest statement
HUS is an employee of Targos Molecular Pathology Inc. and reports research support from Novartis Oncology and received honoraria from MSD, BMS, Roche Pharma, Novartis Oncology, AstraZeneca, Eisai, Takeda, ZytoVision, Zytomed Systems, Molecular Health, outside of the submitted work. All other authors declare no conflict of interest.
References
-
- World Health Organization . Global Tuberculosis Report 2021. World Health Organization; Geneva, Switzerland: 2021. Licence: CC BY-NC-SA 3.0 IGO.
-
- Haworth C.S., Banks J., Capstick T., Fisher A.J., Gorsuch T., Laurenson I.F., Leitch A., Loebinger M.R., Milburn H.J., Nightingale M., et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD) Thorax. 2017;72:ii1–ii64. doi: 10.1136/thoraxjnl-2017-210927. - DOI - PubMed
LinkOut - more resources
Full Text Sources
